Pyxis Oncology (PYXS)

Its lead product candidate is micvotabart pelidotin, also known as MICVO and formerly called PYX-201. MICVO is an investigational antibody-drug conjugate, a class of medicine that links a targeting antibody to a cytotoxic payload. The antibody portion is designed to recognize extradomain-B fibronectin, or EDB+FN, a component of the tumor extracellular matrix. This target is found in a range of tumors and is generally limited in normal adult tissues, making it an attractive marker for selective delivery.

MICVO carries a microtubule inhibitor payload intended to disrupt cancer cell division after release in the tumor microenvironment. The candidate is designed not only to kill cells that bind the antibody-drug conjugate directly, but also to affect neighboring tumor cells through a bystander effect. Pyxis also describes the potential for immunogenic cell death, which could help stimulate broader anti-tumor immune activity.

The company’s initial clinical emphasis includes head and neck squamous cell carcinoma, with broader relevance across solid tumors depending on target expression and trial outcomes. As a development-stage oncology company, Pyxis does not rely on a commercial product franchise; its investment case is tied to clinical data, safety profile, regulatory milestones, intellectual property, and the ability to advance targeted cancer therapies in a competitive antibody-drug conjugate market.